InterVenn’s Glycoproteomic-based Biomarker Signature Successfully Predicts Favorable Outcomes in Metastatic Malignant Melanoma Patients Treated with Checkpoint Inhibitors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #AI--InterVenn Biosciences, the leader in glycoproteomics, announced today that it has developed a glycoproteomics-based signature that accurately predicts which malignant melanoma patients will respond to checkpoint inhibitor therapy. InterVenn’s assay, performed via blood-based liquid biopsy as opposed to a tumor tissue sample, demonstrated that patients...

Click to view original post